CN114835780A - Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers - Google Patents
Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers Download PDFInfo
- Publication number
- CN114835780A CN114835780A CN202210744911.XA CN202210744911A CN114835780A CN 114835780 A CN114835780 A CN 114835780A CN 202210744911 A CN202210744911 A CN 202210744911A CN 114835780 A CN114835780 A CN 114835780A
- Authority
- CN
- China
- Prior art keywords
- cancer
- oligopeptide
- chromatographic column
- treatment
- enzymolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 43
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 title claims description 12
- 240000004160 Capsicum annuum Species 0.000 title abstract 3
- 235000002566 Capsicum Nutrition 0.000 claims description 44
- 239000006002 Pepper Substances 0.000 claims description 31
- 241000722363 Piper Species 0.000 claims description 31
- 235000016761 Piper aduncum Nutrition 0.000 claims description 31
- 235000017804 Piper guineense Nutrition 0.000 claims description 31
- 235000008184 Piper nigrum Nutrition 0.000 claims description 31
- 240000008574 Capsicum frutescens Species 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 235000012054 meals Nutrition 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- 235000019750 Crude protein Nutrition 0.000 claims description 11
- 239000001390 capsicum minimum Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000005238 degreasing Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 150000001450 anions Chemical class 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012460 protein solution Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 241000194108 Bacillus licheniformis Species 0.000 claims description 3
- 230000009849 deactivation Effects 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000012466 permeate Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 108091005658 Basic proteases Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000012264 purified product Substances 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000012465 retentate Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 230000000975 bioactive effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000208293 Capsicum Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000758706 Piperaceae Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- -1 DEAE anion Chemical class 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MTBVQFFQMXHCPC-CIUDSAMLSA-N Met-Glu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MTBVQFFQMXHCPC-CIUDSAMLSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The oligopeptide MEDEI separated from the chilli seeds is separated from the chilli seeds, has an anti-tumor effect, can particularly effectively inhibit the growth and metabolism of HepG2 cells, and has a good application prospect.
Description
Technical Field
The present invention relates to the field of biology. In particular, the invention relates to oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers.
Background
Capsicum, a plant of the genus Capsicum of the family Solanaceae, is native to Mexico, introduced into China, and is now mainly grown in Sichuan, Yunnan, Guizhou, Hunan, Henan, etc. The capsicum mainly comprises capsicum pulp and capsicum seeds, wherein the capsicum seeds account for 30-60% of the dry weight of the capsicum and are main byproducts in the capsicum processing process. The chilli seeds contain rich dietary fiber, fat, protein, mineral substances, vitamin E and the like, and have excellent nutritional and economic values.
With the rapid development of the pepper processing industry in China, peppers are applied to the fields of food, medicine, chemical industry and the like, pepper products such as dried peppers, pepper sauce, pepper powder, hotpot condiment and the like in the food field are more and more, capsaicin is widely applied to medicine, and a large amount of waste pepper seeds can be generated in the pepper processing process. At present, a small part of pepper seeds in China are used as animal feed, but most of the pepper seeds are not effectively utilized and treated as waste, so that environmental pollution and resource waste are caused. The pepper seeds have high yield, low price and easy acquisition, and the cake protein has complete amino acids and moderate essential amino acid content, thereby being a high-quality protein resource. Therefore, the bioactive peptide extracted from the chilli seeds can change waste into valuable, improve the resource utilization rate, reduce pollution and meet the development target of an environment-friendly society.
At present, antitumor drugs such as fluorouracil, cisplatin, daunorubicin and the like play an important role in tumor treatment, but the safety, the effectiveness, the high price and the like of the drugs limit the clinical application of the drugs. More and more studies have shown that bioactive peptides from natural foods or animals and plants have a positive effect on human health. The physiological activity function of the bioactive peptide is mainly embodied in the aspects of antibiosis, antivirus, antioxidation, antitumor, blood sugar reduction, blood pressure reduction, cholesterol reduction, immunoregulation and the like, the bioactive peptide of animal source has the problems of high cost, safety and the like, the bioactive peptide of plant source is widely applied due to pure nature and high nutritional value, such as the bioactive peptide of soybean, the bioactive peptide of peanut, the bioactive peptide of rapeseed and the like, but the research on the bioactive peptide in the chilli seed is less.
Disclosure of Invention
The present invention aims to solve at least to some extent at least one of the technical problems of the prior art.
In one aspect of the invention, the invention features an isolated polypeptide. According to an embodiment of the invention, the isolated oligopeptide has the amino acid sequence as shown in SEQ ID NO: 1 or a functional analogue thereof, and specifically, the amino acid sequence of the isolated oligopeptide is MEDEI (Met-Glu-Asp-Glu-IlE, SEQ ID NO: 1). The oligopeptide is separated from pepper seeds and the function of the oligopeptide is researched, so that the oligopeptide has an anti-tumor effect, particularly can effectively inhibit the growth and metabolism of HepG2 cells, and has a good application prospect.
According to an embodiment of the present invention, the isolated oligopeptide is derived from capsicum seeds. The inventor extracts protein in pepper seeds and unexpectedly discovers the oligopeptide with the anti-tumor effect.
In another aspect of the invention, the invention features a nucleic acid molecule. According to an embodiment of the invention, the nucleic acid molecule encodes an isolated oligopeptide as described above. The nucleic acid molecules according to the embodiments of the present invention, after introduction into recipient cells, express the aforementioned isolated oligopeptides having an antitumor effect in an environment suitable for protein expression.
In the present invention, the sequence of the nucleic acid molecule is not strictly limited as long as it encodes the isolated oligopeptide described above.
In yet another aspect of the invention, the invention features a construct. According to an embodiment of the invention, the construct comprises a nucleic acid molecule as described above. After the constructs according to the embodiments of the present invention are introduced into cells, the isolated oligopeptides described above are expressed under an environment suitable for protein expression, which helps to exert the antitumor effect of the oligopeptides.
In yet another aspect of the invention, the invention features a recombinant cell. According to an embodiment of the invention, the recombinant cell comprises a nucleic acid molecule as described above or a construct as described above. Thus, the aforementioned oligopeptide is expressed under an environment suitable for protein expression, and contributes to the antitumor effect of the oligopeptide. The recombinant cells of the invention do not comprise germ cells, fertilized egg cells or embryonic cells.
In yet another aspect of the invention, a medicament or food product is provided. According to an embodiment of the invention, the medicament or food product comprises: an isolated oligopeptide, nucleic acid molecule or recombinant cell as hereinbefore described. Thus, the drug or food according to the embodiment of the present invention has an effect of preventing or treating cancer.
In a further aspect of the invention, the invention provides the use of an oligopeptide, nucleic acid molecule or recombinant cell as hereinbefore described in the manufacture of a medicament or a food product. According to an embodiment of the present invention, the medicament or food is for preventing or treating cancer.
According to an embodiment of the present invention, the cancer is breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, stomach cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, thyroid cancer, lymphoma, bladder cancer, kidney cancer, uterine body cancer, ovarian cancer, gall bladder cancer, oral cancer, laryngeal cancer, bone cancer, testicular cancer, or brain cancer.
In yet another aspect of the invention, the invention provides a method for obtaining the isolated oligopeptides described above. According to an embodiment of the invention, the method comprises: and (3) processing the pepper seeds to obtain the separated oligopeptide.
According to an embodiment of the invention, the method comprises: (1) crushing the chilli seeds to obtain chilli seed meal; (2) degreasing the pepper seed meal to obtain degreased pepper seed meal; (3) extracting protein in the degreased pepper seed meal to obtain a crude protein extract; (4) carrying out enzymolysis treatment on the crude protein extract, and then inactivating enzyme to obtain an enzymolysis protein solution; (5) and separating and purifying the enzymolysis protein solution to obtain the separated oligopeptide.
In the step (1), the pepper seeds are crushed so as to better perform subsequent reaction, so that the reaction is more sufficient, and the yield and the purity of the oligopeptide are improved. In the step (2), grease in the pepper seed meal can be removed through degreasing treatment, so that the extraction rate and the purity of the protein are improved. In the step (4), the proteolysis treatment can effectively decompose the protein into small molecular peptides, which is helpful for obtaining oligopeptides with anticancer function.
According to the embodiment of the invention, in the step (1), the crushed material obtained by crushing is sieved by a sieve of 60-100 meshes to obtain a trapped material and a permeated material, and the permeated material is collected to obtain the pepper seed meal. Therefore, the pepper seed powder can permeate through the membrane, impurities can be intercepted, the protein extraction rate is improved, and the influence of the impurities is avoided.
According to the embodiment of the invention, the degreasing solvent used in the degreasing treatment is n-hexane. Thus, the fat can be effectively removed, and the use is safe.
According to an embodiment of the present invention, step (3) comprises: and mixing the degreased pepper seed meal with water, adjusting the pH value of the obtained mixed solution to 9-10 by using alkali liquor, reacting for 3-5 hours, adjusting the pH value of the reaction solution to 4-5, reacting for 1-3 hours, centrifuging the reaction solution, and collecting precipitates to obtain a crude protein extract. The pH value is firstly high because the protein in the pepper seed meal can be dissolved out under the alkaline environment, then the pH value is reduced because the protein can be settled at the isoelectric point of the protein, and the separated protein can be obtained after centrifugation.
According to an embodiment of the present invention, the crude protein extract is subjected to an ultra-high pressure treatment in advance before the enzymatic treatment in step (4). The ultra-high pressure treatment can improve the physicochemical property of protein, and the activity of the product after ultra-high pressure and enzymolysis is higher than that of the product only subjected to enzymolysis.
According to the embodiment of the invention, the pressure of the ultrahigh pressure treatment is 100-400 MPa, and the time is 20-40 minutes. Therefore, the protein is beneficial to improving the physicochemical property of the protein and improving the activity of the product obtained by enzymolysis.
According to the embodiment of the invention, the temperature of the enzymolysis treatment is 30-50 ℃, the time is 1-5 hours, the pH value is 7-10, the enzyme adopted by the enzymolysis treatment is selected from alkaline protease, preferably bacillus licheniformis, and the mass ratio of the enzyme to the crude protein is 1: 20-1: 50. Thereby, the protein is decomposed into small molecular peptide, so that the anticancer oligopeptide can be obtained.
According to the embodiment of the invention, the enzyme deactivation is carried out for 1-10 min at 90-100 ℃. Thereby, to inactivate the enzyme, prevent over-reaction or prevent the enzyme from interfering with subsequent experiments.
According to the embodiment of the invention, in the step (5), the separation and purification are performed by using a chromatographic column, wherein the chromatographic column is an anion chromatographic column or a hydrophobic chromatographic column; when the chromatographic column is an anion chromatographic column, the adopted mobile phase is water and NaCl; when the chromatographic column is a hydrophobic chromatographic column, the adopted mobile phase is water and 40-60 v/v% methanol solution.
According to an embodiment of the present invention, in the step (5), the separation and purification includes: injecting the enzymolysis protein solution into an anion chromatographic column, eluting with a mobile phase, and collecting an effluent liquid within 35-45 min; injecting the effluent into a hydrophobic chromatographic column, eluting by using a mobile phase, and collecting the effluent within 75-90 min so as to obtain a purified product containing the oligopeptide.
The inventors have conducted extensive experiments to obtain the above-mentioned preferable separation and purification method, and thus, the isolated oligopeptide can be obtained.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
The above and/or additional aspects and advantages of the present invention will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
FIG. 1 shows a schematic diagram of the analysis of the effect of different peptides on HepG2 cell proliferation according to one embodiment of the present invention.
Detailed Description
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Example 1
In this example, the oligopeptide MEDEI in the pepper seeds was extracted as follows:
1) removing seeds: separating fresh pepper seed meat to obtain pepper seeds;
2) crushing: grinding the chilli seeds into chilli seed meal, and sieving the chilli seed meal with a 80-mesh sieve to obtain chilli seed powder;
3) degreasing: mixing the pepper seed meal and normal hexane according to a ratio of 1:10 (g/ml), stirring overnight for degreasing, and removing the normal hexane by adopting a suction filtration mode after degreasing is finished to obtain pepper seed meal;
4) protein extraction: dissolving the degreased pepper seed meal in water at a ratio of 1:10 (w/v, unit g/mL), adjusting the pH value of the solution to 9.5 by using NaOH solution, dissolving for 4 h, adjusting the pH value of the solution to 4.5 by using HCl, precipitating for 2 h, centrifuging the reaction solution at 8000 rpm for 20min, and collecting precipitate to obtain a crude protein extract;
5) ultra-high pressure auxiliary enzymolysis: dissolving the protein isolate in water, carrying out ultrahigh pressure treatment for 30min under the pressure of 300 MPa, and then carrying out enzymolysis treatment on a product obtained by the ultrahigh pressure treatment, wherein the enzyme is bacillus licheniformis, and the mass ratio of the enzyme to the substrate is 1:20 (w/w, unit g/g), 40 ℃, and adjusting the pH value to 8 by using 1mol/L NaOH for 3 hours;
6) enzyme deactivation: after enzymolysis is finished, inactivating enzyme for 10 minutes at 90 ℃ to obtain chilli seed zymolyte solution;
7) and (3) separating and purifying zymolyte: and (2) enabling the chilli seed zymolyte solution to pass through A DEAE anion chromatographic column, collecting eluent in A35-45 min time period by using deionized water and NaCl as mobile phases, then separating and purifying by using an ODS-A reversed-phase C18 column (A hydrophobic column), collecting eluent in A75-90 min time period by using deionized water and 50% methanol as the mobile phases. And carrying out mass spectrum identification analysis on the peptide segments in the obtained eluent to obtain a plurality of pieces of peptide sequence information.
Example 2
The peptide sequence obtained by mass spectrometric analysis of example 1 was chemically synthesized to give a synthetic peptide. The influence of each peptide on the proliferation of HepG2 cells is respectively researched, and the specific steps are as follows:
1) HepG2 cell culture: HepG2 cells were derived from ATCC cell bank, and HepG2 cells were cultured in DMEM medium containing 10% FBS in a growth environment of 5% carbon dioxide cell incubator at 37 ℃. At 25cm 2 Culturing the cells in a culture flask, carrying out passage when the cells grow to the density of 70-90%, and inoculating the cells into a 96-well plate.
2) Peptide fragment treatment: after the cells in the 96-well plate are cultured for 24 hours, the original DMEM culture medium in the wells is sucked out, DMEM containing peptide segments is added into each well, the concentration of the peptide segments is 0.1, 0.3 and 0.6mM, and the culture is continued for 24 hours.
3) The MTT method is used for measuring the cell proliferation rate: mu.L of MTT was added to each well of the 96-well plate at a concentration of 5mg/mL, after 4 hours of incubation, the liquid was aspirated from each well, 150. mu.L of DMSO was added to each well, and the absorbance was measured after 20min of reaction.
As shown in fig. 1, it can be seen that oligopeptide MEDEI has a better HepG2 cell inhibition rate than other oligopeptides, and is helpful for preventing or treating liver cancer.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
SEQUENCE LISTING
<110> university of agriculture in China
<120> oligopeptide MEDEI isolated from capsicum seed and its use in preventing or treating cancer
<130> BI3220848
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> 1
<400> 1
Met Glu Asp Glu Ile
1 5
Claims (12)
1. An isolated oligopeptide, wherein the amino acid sequence of the isolated oligopeptide is SEQ ID NO: 1.
2. the isolated oligopeptide according to claim 1, wherein the isolated oligopeptide is derived from capsicum seeds.
3. A nucleic acid molecule encoding the isolated oligopeptide of claim 1 or 2.
4. A construct comprising the nucleic acid molecule of claim 3.
5. A recombinant cell comprising the nucleic acid molecule of claim 3 or the construct of claim 4.
6. A medicament or food product, comprising: the isolated oligopeptide of claim 1 or 2, the nucleic acid molecule of claim 3 or the recombinant cell of claim 5.
7. Use of the isolated oligopeptide according to claim 1 or 2, the nucleic acid molecule according to claim 3 or the recombinant cell according to claim 5 in the preparation of a medicament or a foodstuff for the prevention or treatment of cancer.
8. The use according to claim 7, wherein the cancer is breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, stomach cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, thyroid cancer, lymphoma, bladder cancer, kidney cancer, uterine body cancer, ovarian cancer, gallbladder cancer, oral cancer, laryngeal cancer, bone cancer, testicular cancer, or brain cancer.
9. A method for obtaining an isolated oligopeptide according to claim 1 or 2, comprising:
and (3) processing the pepper seeds to obtain the separated oligopeptide.
10. The method of claim 9, comprising:
(1) crushing the chilli seeds to obtain chilli seed powder;
(2) degreasing the chilli seed powder to obtain degreased chilli seed meal;
(3) extracting protein in the degreased pepper seed meal to obtain a crude protein extract;
(4) carrying out enzymolysis treatment on the crude protein extract, and then inactivating enzyme to obtain an enzymolysis protein solution;
(5) and separating and purifying the enzymolysis protein solution to obtain the separated oligopeptide.
11. The method according to claim 10, wherein in the step (1), the crushed material obtained by crushing is sieved by a sieve of 60-100 meshes to obtain a retentate and a permeate, and the permeate is collected to obtain the pepper seed meal;
in the step (2), a degreasing solvent adopted in the degreasing treatment is n-hexane;
the step (3) comprises the following steps: mixing the degreased pepper seed meal with water, adjusting the pH value of the obtained mixed solution to 9-10 by using alkali liquor, reacting for 3-5 hours, adjusting the pH value of the reaction solution to 4-5, reacting for 1-3 hours, centrifuging the reaction solution, and collecting precipitates to obtain a crude protein extract;
before the enzymolysis treatment in the step (4), performing ultrahigh pressure treatment on the crude protein extract in advance;
the pressure of the ultrahigh pressure treatment is 100-400 MPa, and the time is 20-40 minutes;
the temperature of the enzymolysis treatment is 30-50 ℃, the time is 1-5 hours, and the pH value is 7-10;
the enzyme adopted by the enzymolysis treatment is selected from alkaline protease, and the mass ratio of the enzyme to the crude protein is 1: 20-1: 50;
the enzyme deactivation is carried out for 1-10 min at the temperature of 90-100 ℃;
in the step (5), the separation and purification are carried out by adopting a chromatographic column, wherein the chromatographic column is an anion chromatographic column and a hydrophobic chromatographic column; when an anion chromatographic column is used, the mobile phase used comprises water and NaCl; when a hydrophobic chromatographic column is adopted, the adopted mobile phase comprises water and 40-60 v/v% methanol solution.
12. The method according to claim 10 or 11, wherein the enzyme used in the enzymatic treatment is selected from the group consisting of bacillus licheniformis;
in the step (5), the separation and purification comprises:
injecting the enzymolysis protein solution into an anion chromatographic column, eluting with a mobile phase, and collecting an effluent liquid within 35-45 min;
injecting the effluent into a hydrophobic chromatographic column, eluting by using a mobile phase, and collecting the effluent within 75-90 min so as to obtain a purified product containing the oligopeptide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210744911.XA CN114835780B (en) | 2022-06-29 | 2022-06-29 | Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210744911.XA CN114835780B (en) | 2022-06-29 | 2022-06-29 | Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114835780A true CN114835780A (en) | 2022-08-02 |
CN114835780B CN114835780B (en) | 2022-09-27 |
Family
ID=82574734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210744911.XA Active CN114835780B (en) | 2022-06-29 | 2022-06-29 | Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114835780B (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1659276A (en) * | 2002-04-19 | 2005-08-24 | 戴弗萨公司 | Phospholipases, nucleic acids encoding them and methods for making and using them |
WO2006096392A2 (en) * | 2005-03-04 | 2006-09-14 | Diversa Corporation | Enzymes involved in astaxanthin, carotenoid and isoprenoid biosynthetic pathways, genes encoding them and methods of making and using them |
CN101291683A (en) * | 2004-11-24 | 2008-10-22 | 纽普罗研究有限公司 | Methods and compositions for treating conditions |
WO2011052846A1 (en) * | 2009-11-02 | 2011-05-05 | 한국과학기술연구원 | Pharmaceutical composition containing extracts of native plants as active ingredients for preventing or treating cancer |
CN102408470A (en) * | 2005-12-23 | 2012-04-11 | 洛桑大学 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
CN105132506A (en) * | 2015-09-28 | 2015-12-09 | 昆明理工大学 | Preparation method of chili seed antibacterial peptide |
CN108586570A (en) * | 2018-05-16 | 2018-09-28 | 西南大学 | A kind of method for extraction and purification of capsicum antibacterial peptide |
CN114617249A (en) * | 2022-04-12 | 2022-06-14 | 湖南农业大学 | Production process of chili sauce and product thereof |
-
2022
- 2022-06-29 CN CN202210744911.XA patent/CN114835780B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1659276A (en) * | 2002-04-19 | 2005-08-24 | 戴弗萨公司 | Phospholipases, nucleic acids encoding them and methods for making and using them |
CN102174546A (en) * | 2002-04-19 | 2011-09-07 | 维莱尼姆公司 | Phospholipases, nucleic acids encoding them and methods for making and using them |
CN101291683A (en) * | 2004-11-24 | 2008-10-22 | 纽普罗研究有限公司 | Methods and compositions for treating conditions |
WO2006096392A2 (en) * | 2005-03-04 | 2006-09-14 | Diversa Corporation | Enzymes involved in astaxanthin, carotenoid and isoprenoid biosynthetic pathways, genes encoding them and methods of making and using them |
CN102408470A (en) * | 2005-12-23 | 2012-04-11 | 洛桑大学 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
WO2011052846A1 (en) * | 2009-11-02 | 2011-05-05 | 한국과학기술연구원 | Pharmaceutical composition containing extracts of native plants as active ingredients for preventing or treating cancer |
CN105132506A (en) * | 2015-09-28 | 2015-12-09 | 昆明理工大学 | Preparation method of chili seed antibacterial peptide |
CN108586570A (en) * | 2018-05-16 | 2018-09-28 | 西南大学 | A kind of method for extraction and purification of capsicum antibacterial peptide |
CN114617249A (en) * | 2022-04-12 | 2022-06-14 | 湖南农业大学 | Production process of chili sauce and product thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114835780B (en) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109293740B (en) | Oyster-derived ACE (angiotensin converting enzyme) inhibitory and antitumor active peptide | |
CN109251954B (en) | Production method of sea cucumber polypeptide | |
CN114835774B (en) | Oligopeptide MSL separated from pepper seeds and application thereof in preventing or treating cancers | |
KR102258788B1 (en) | Novel Aspergillus niger C2-2 isolated from Nu-ruk producing ginsenoside compound K biotransformation enzyme and use thereof | |
CN105713945A (en) | Preparation method of scallop antioxidant peptide | |
CN109206483B (en) | ACE (angiotensin converting enzyme) inhibition and anti-tumor active peptide from mussels | |
CN114835780B (en) | Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers | |
CN114853847B (en) | Oligopeptide FTLE separated from pepper seeds and application thereof in preventing or treating cancers | |
CN113106138A (en) | Preparation method for extracting and separating anti-tumor active protein from shiitake mushrooms | |
JP5399468B2 (en) | Composition exhibiting lipolytic activity | |
JP6388201B2 (en) | Carotenoid derivatives with cytokeratin increasing action | |
CN111825745B (en) | Immunoregulatory active heptapeptide and preparation method and application thereof | |
CN113999288A (en) | Polypeptide with proliferation promoting function prepared from fish leftovers | |
CN113372461A (en) | Method for extracting selenium polysaccharide with high antioxidant activity from selenium-rich passion fruit peel | |
KR20120079977A (en) | Anticancer composition comprising enzymatic hydrolysates of ruditapes philippinarum | |
KR101975016B1 (en) | Method for producing rare ginsenosides from ginseng berry by the combination of steaming process and enzyme treatment | |
JP6751838B2 (en) | Neuraminic acid derivative exhibiting Langerhans cell activating action and its production method | |
Chandimali et al. | Bioactive peptides derived from duck products and by-products as functional food ingredients | |
CN111848735B (en) | Immunoregulation active peptide and preparation method and application thereof | |
JP6629512B2 (en) | Composition for promoting collagen production containing glucosylceramide derived from Torula yeast | |
Shao et al. | Isolation, antioxidant and antitumor in vitro activities of cold pressed green tea seed cake polysaccharide | |
JP2011217696A (en) | Method for producing pinitol or pinitol-containing composition, and microorganism used for the same | |
WO2023276167A1 (en) | Sirtuin activator | |
CN107630062B (en) | Preparation method of hippocampus kelloggi ACE inhibitory peptide | |
CN117903280A (en) | Preparation method and application of placenta caprae seu ovis anti-tumor protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |